Eight other lawsuits winding their way through the courts don't involve providers, so even if they hit a roadblock, it likely won't be for the same reason.
Just 2,000 patients have been treated so far with Leqembi, Biogen said Tuesday, a warning that the Alzheimer's drug developed with Eisai Co. may miss its target of 10,000 recipients by the end of March.
Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.